Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $5.5800 (1.45%) ($5.4200 - $6.0500) on Fri. Oct. 12, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.47% (three month average) | RSI | 25 | Latest Price | $5.5800(1.45%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 0.6% a day on average for past five trading days. | Weekly Trend | TGTX declines -5.5% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Rotation from value to growth for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) SHY(7%) XHB(6%) DIA(5%) TLT(5%) IPO(4%) | Factors Impacting TGTX price | TGTX will decline at least -3.235% in a week (0% probabilities). XLC(-8%) URA(-8%) ICLN(-7%) BLOK(-7%) XLRE(-6%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.235% (StdDev 6.47%) | Hourly BBV | 0 () | Intraday Trend | -1.1% | | | |
|
Resistance Level | $6.47 | 5 Day Moving Average | $5.48(1.82%) | 10 Day Moving Average | $5.46(2.2%) | 20 Day Moving Average | $6.47(-13.76%) | To recent high | -58.5% | To recent low | 8.3% | Market Cap | $707m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |